Jason Y. Zhang

Jason Y. Zhang

Auto-generated profile, based on publicly available information

Jason Y. Zhang

Pritzker School of Medicine, University of Chicago, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in Neuron
Verified
Journal Article
Closed access
MVMatthew B. Veldman
Matthew B. Veldman
CPChang Sin Park
Chang Sin Park
CECharles M. Eyermann
Charles M. Eyermann
JZJason Y. Zhang
Jason Y. Zhang
EZElizabeth Zuniga-Sanchez
Elizabeth Zuniga-Sanchez
XYX. William Yang
X. William Yang

6 May 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
JXJason Xiao
Jason Xiao
JZJason Y. Zhang
Jason Y. Zhang
WLWendy Luo
Wendy Luo
PHP. Cody He
P. Cody He
Dimitra SkondraDimitra Skondra
Dimitra Skondra

11 February 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
JZJason Y. Zhang
Jason Y. Zhang
MGMark J. Greenwald
Mark J. Greenwald
SRSarah H Rodriguez
Sarah H Rodriguez

Verified
Journal Article
Open access
PDF file
JZJason Y. Zhang
Jason Y. Zhang
BXBingqing Xie
Bingqing Xie
HBHugo Adrian Barba
Hugo Adrian Barba
UNUrooba Nadeem
Urooba Nadeem
Asadolah MovahedanAsadolah Movahedan
Asadolah Movahedan
Dimitra SkondraDimitra Skondra
Dimitra Skondra
Studies have begun to reveal significant connections between the gut microbiome and various retinal diseases, including age-related macular degeneration (AMD). As critical supporting tissues of the retina, the retinal pigment epithelium (RPE) and underlying choroid play a critical role in retinal homeostasis and degeneration. However, the relationship between the microbiome and RPE/choroid remains poorly understood, particularly in animal models of AMD. In order to better elucidate this role, we performed high-throughput RNA sequencing of RPE/choroid tissue in germ-free (GF) and specific pathogen-free (SPF) mice. Furthermore, utilizing a specialized laser-induced choroidal neovascularization (CNV) model that we developed, we compared CNV size and inflammatory response between GF and SPF mice. After correction of raw data, 660 differentially expressed genes (DEGs) were identified, including those involved in angiogenesis regulation, scavenger and cytokine receptor activity, and inflammatory response—all of which have been implicated in AMD pathogenesis. Among lasered mice, the GF group showed significantly decreased CNV lesion size and microglial infiltration around CNV compared to the SPF group. Together, these findings provide evidence for a potential gut–RPE/choroidal axis as well as a correlation with neovascular features of AMD.

16 July 2023 in Ophthalmology Glaucoma
Verified
Journal Article
Closed access
JZJason Y. Zhang
Jason Y. Zhang
MQMary Qiu
Mary Qiu

27 January 2021 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JSJennifer Sheng
Jennifer Sheng
JZJason Zhang
Jason Zhang
CBChristine Baudelet
Christine Baudelet
ARAmit Roy
Amit Roy
Nivolumab 240 mg every 2 weeks is approved in China by the National Medical Product Agency for squamous cell carcinoma of the head and neck and gastric cancer, based on population pharmacokinetic (PPK) analyses and benefit‐risk assessment of safety/efficacy in solid tumors, including Chinese and global populations. The aim of this assessment was to investigate exposure and risk for adverse events (AEs) with flat dosing compared with weight‐based dosing. Nivolumab 240‐mg and 3‐mg/kg every‐2‐week exposures in Chinese patients were simulated using PPK modeling, and AEs in Chinese and pooled global populations were compared by dosing regimen, exposure, and weight. The 10‐mg/kg every‐2‐week regimen was included because it is known to be well tolerated. Predicted nivolumab exposure in Chinese patients receiving 240 mg every 2 weeks was ∼25% higher versus 3 mg/kg every 2 weeks, but ∼60% lower versus 10 mg/kg every 2 weeks. Grade 3/4 AE incidence in Chinese patients receiving nivolumab 3 mg/kg every 2 weeks was similar with 240‐mg every‐2‐week dosing and with patients from global populations treated with 3 or 10 mg/kg every 2 weeks. There was no trend toward increased AE incidence with high versus low nivolumab exposure or in global patients of varying body weight receiving 3 or 10 mg/kg every 2 weeks. Objective response rates were similar in Chinese and global patients with squamous and nonsquamous NSCLC. Results showed that benefit‐risk profiles with nivolumab 240 mg every 2 weeks were similar to those of the 3‐mg/kg every‐2‐week regimen in Chinese patients and global populations, providing an alternative treatment option to Chinese patients.